Evidence map›Paper›PMID 34200874›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report.

Thierry Alcindor, Sungmi Jung, Lucy Gilbert

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Thierry AlcindorCedars Cancer Center, Division of Medical Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
Sungmi JungDepartment of Pathology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
Lucy GilbertCedars Cancer Center, Division of Gynecologic Oncology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
McGill University Health Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 32-year-old woman with chemorefractory mullerian adenosarcoma showed clinical benefit in response to administration of lenvatinib plus pembrolizumab. In this case report, we describe the course of her illness and her response to this treatment.

Indexed as

AdenosarcomaAdultAntibodies, Monoclonal, HumanizedFemaleHumansPhenylurea CompoundsQuinolinesAntibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolinesadenosarcomaimmunotherapysarcomatargeted therapy

Identifiers

PMID34200874
PMCPMC8293099
OpenAlexW3166769431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.